人类药物开始第1阶段试验,进行新的自发免疫障碍治疗,即MKP11093。 Mankind Pharma begins Phase 1 trials for new autoimmune disorder treatment, MKP11093.

印度的CDSCO批准了Mankind Pharma开始对MKP11093新分子进行第一阶段临床试验,该分子旨在治疗类风湿性关节炎,性结肠炎,斑块性牛皮和脱发等自身免疫性疾病. Mankind Pharma has been approved by India's CDSCO to start Phase 1 clinical trials for a new molecule, MKP11093, aimed at treating autoimmune disorders like rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and alopecia. 这一分子在临床预科研究中表现出了很有希望的安全性。 This molecule has shown promising safety in preclinical studies. 即将进行的试验将通过各种剂量研究,评估健康志愿者的安全和药理动力学。 The upcoming trial will assess its safety and pharmacokinetics in healthy volunteers through various dose studies.